Kinex bags first partner for lead molecule
This article was originally published in Scrip
Executive Summary
Kinex Pharmaceuticals has licensed out rights to its lead development project KX01 (KX2-391) for most Asian countries to South Korea's Hanmi Pharmaceuticals, in a deal that will enable the privately held US firm to tap into the potential of the growing markets in the region, including China.